News & Updates
Showing Pharmacy articles
Showing
Survival benefit with postchemoradiation immunotherapy affirmed
Starting immunotherapy after chemotherapy and radiation for unresectable stage III nonsmall cell lung cancer (NSCLC) prolongs overall survival, regardless of patient age, health, and socioeconomic status, according to a large US study.
Survival benefit with postchemoradiation immunotherapy affirmed
15 Aug 2022
Subgroup analyses boost masupirdine potential for AD
Post hoc data from a phase II study presented at AAIC 2022 continue to demonstrate the potential of masupirdine (SUVN-502), a selective 5-HT6 receptor antagonist, as a treatment alternative for the management of neuropsychiatric and cognitive symptoms of Alzheimer’s disease (AD).
Subgroup analyses boost masupirdine potential for AD
15 Aug 2022
HCV reinfection highest among people with ongoing injecting drug use
Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.
HCV reinfection highest among people with ongoing injecting drug use
14 Aug 2022
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.